Mid-sized dermatology specialist Maruho Co. Ltd. has licensed in selected rights in Japan to a novel antibody from Chugai Pharmaceutical Co. Ltd.and in global markets to a Janus kinase (JAK) inhibitor developed by Astellas Pharma Inc.
In licensing to Maruho the Japanese rights to develop and market nemolizumab (CIM331) for skin disorders, Chugai has taken a...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
